May 24, 2017
Patients with hepatocellular carcinoma and hepatitis C were less likely to achieve sustained virologic response while receiving direct-acting antiviral therapy compared with patients without HCC, according to results of a retrospective study.
“Our data demonstrate that the presence of active HCC at the initiation of HCV therapy is significantly associated with DAA treatment failure,” Stacey B. Prenner, MD, from Northwestern University, Chicago, and colleagues wrote. “In contrast, DAA therapy in the presence of inactive tumor or post removal of tumor (resection/transplant) resulted in excellent SVR rates, similar to patients without HCC. There may be a trade-off in optimizing HCV clearance and risk of recurrent HCC depending upon the immunologic properties of an individual tumor.”